Featured

2016 in Review: A Psychopharmacology Update for Clinicians

Author: Flavio Guzman, MD Dr. Guzman has no conflicts of interest to disclose. In this article we take a look back at the most clinically relevant news of 2016 in the field of psychopharmacology. In terms of new drugs, only one new molecular entity of psychiatric interest was approved (Pimavanserin, for Parkinson’s disease psychosis). We…

Read More

Antidepressant Discontinuation Syndrome: Diagnosis, Prevention and Management

Author: Flavio Guzman, MD Discontinuation symptoms can occur with all antidepressant classes, and you will see many articles referring to SSRI discontinuation syndrome. The reason is that SSRIs are by far the most commonly prescribed antidepressant class. This syndrome consists of usually mild and reversible symptoms that can be grouped into six categories. As a…

Read More

Lithium’s Mechanism of Action: An Illustrated Review

Author: Flavio Guzman, MD Lithium’s mechanism involves multiple levels of action, from macroscopic neuroprotective effects to intracellular changes. This tutorial discusses: Brain abnormalities found in patients suffering from bipolar disorder How lithium modulates dopamine, glutamate and GABA Intracellular changes associated with lithium use (effects on proteins such as PKC, MARCKS, GSK-3, IPPase and IMPase) Unravelling…

Read More

Long-Acting Injectable Antipsychotics: A Practical Guide for Prescribers

Author: Flavio Guzman, MD Competing interests: none This article summarizes the most clinically relevant features of long-acting injectable antipsychotics (LAIs, previously known as depot antipsychotics). We discuss general concepts as well as key prescribing facts of individual agents. The guide also includes two new formulations: aripiprazole lauroxil (Aristada) and 3-month paliperidone palmitate (Invega Trinza). Advantages and disadvantages of long-acting antipsychotics…

Read More